Lemtrada Patients At Extreme Risk From COVID-19

Lemtrada Stroke Lawsuit News

Lemtrada is one of the most toxic drugs and could be responsible for magnifying the symptoms of the Novel Coronavirus

Wednesday, April 8, 2020 - Patients suffering from Relapse Remitting Multiple Sclerosis (RRMS) need to take extra precautions as taking Lemtrada puts them in the highest possible risk for contracting the deadly novel Coronavirus. As it was, RRMS patients try Lemtrada, which has proven to be highly effective in treating RRMs symptoms, only when all other possible alternative therapies have failed. The reason why Lemtrada is considered a hail mary attempt to alleviate RRMS is because patients have suffered spontaneous strokes and heart attacks while receiving or within 48 hours of a Lemtrada treatment infusion. Lemtrada toxicity can destroy the delicate inner lining of the arterial veins leading to the brain, lungs, and heart causing blood clots to spontaneously develop and break free, causing blockages and instant paralysis or death. Lemtrada may only be administered after the patient and doctor complete and sign a lengthy questionnaire demonstrating they both understand the potential for harm that the drug carries. The European Pharmaceutical Review warns of Lemteada's side effects as " "Unpredictable and potentially fatal immune-mediated reactions can occur within months and up to at least four years after treatment with the drug. Reactions included autoimmune hepatitis, haemophagocytic lymphohistiocytosis, and acquired hemophilia A. The review identified serious cases of Epstein-Barr virus reactivation reported after treatment, including hepatitis. Some patients developed more than one autoimmune disorder following treatment." Lemtrada attorneys helping families nationwide, offer a free consultation and no obligation to file a claim.

Deaths from Coronavirus have been limited mainly to the elderly and patients that take potent disease-modifying drugs to treat life-threatening illnesses and have weakened autoimmune systems. As a result of the newest layer of Lemtrada risk, Multiple Sclerosis News Today has published a set of guidelines that every doctor and patient taking or seeking information on taking Lemtrada needs to know. Individuals with RRMS taking Lemtrada have to weigh the benefits of taking the drug against the risk of being the ones who die from the Coronavirus.

If any country should know about the Coronovirus first hand it is the nation of Italy, the country hardest hit by the Coronavirus. At last count, there were 115,242 cases of Coronavirus reported resulting in 13,915 deaths in the small European nation. Health officials there recommend delaying the start of treatments using Ocrevus, (alemtuzumab), Rituxan (rituximab), and Mavenclad (cladribine) and patients already receiving treatments using these medications should monitor their health daily. Both Italy and the United Kingdom caution that coronavirus infections and lung irritation could be much more severe in patients taking these drugs. Elderly individuals that take Lemtrada are at particularly high risk from the Coronavirus and should consider stopping their high-risk disease-modifying treatment (DMT).

It would be a particularly good idea for Lemtrada patients that elect to continue taking the treatment to practice strict quarantine procedures during the next several months to see if the virus runs its course. Traveling anywhere by bus, cruise, plane or any other closed transportation system should be avoided.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.